HUP9902076A2 - Szexuális rendellenességek kezelésére alkalmas intranazális készítmény - Google Patents

Szexuális rendellenességek kezelésére alkalmas intranazális készítmény

Info

Publication number
HUP9902076A2
HUP9902076A2 HU9902076A HUP9902076A HUP9902076A2 HU P9902076 A2 HUP9902076 A2 HU P9902076A2 HU 9902076 A HU9902076 A HU 9902076A HU P9902076 A HUP9902076 A HU P9902076A HU P9902076 A2 HUP9902076 A2 HU P9902076A2
Authority
HU
Hungary
Prior art keywords
derivative
sexual disorders
dihydrate
mesylate
treating sexual
Prior art date
Application number
HU9902076A
Other languages
English (en)
Inventor
Anne Billotte
Peter James Dunn
Brian Thomas Henry
Peter Valence Marshall
Joanna Jayne Woods
Original Assignee
Pfizer Research And Development Co.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9813452.1A external-priority patent/GB9813452D0/en
Priority claimed from GBGB9820837.4A external-priority patent/GB9820837D0/en
Priority claimed from GBGB9903177.5A external-priority patent/GB9903177D0/en
Application filed by Pfizer Research And Development Co., filed Critical Pfizer Research And Development Co.,
Publication of HU9902076D0 publication Critical patent/HU9902076D0/hu
Publication of HUP9902076A2 publication Critical patent/HUP9902076A2/hu
Publication of HUP9902076A3 publication Critical patent/HUP9902076A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Abstract

A találmány őlyan, intranazálisan beadható gyógyászati készítményekrevőnatkőzik, amelyek hatóanyagként sildenafil-mezilátőt vagy ennekmőnő- vagy dihidrátját tartalmazzák a gyógyszergyártásban szőkásősanhasznált hőrdőzó- és/vagy egyéb segédanyagőkkal együtt intranazálisbeadásra adaptált főrmában. A találmány szerinti gyógyászatikészítmények lehetnek főlyékőny halmazállapőtúak, célszerűen pűfferőltőldatők vagy szilárd pőrkészítmények. A találmány szerinti gyógyászatikészítményekkel férfiaknál merevedési rendellenesség, illetve nőknélkülönböző szexűális zavarők kezelhetők. A találmány tővábbá magára asildenafil-mezilátra, valamint ennek mőnő- vagy dihidrátjáravőnatkőzik. ŕ
HU9902076A 1998-06-22 1999-06-21 Intranasal formulations for treating sexual disorders HUP9902076A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9813452.1A GB9813452D0 (en) 1998-06-22 1998-06-22 Pharmaceutical formulations
GBGB9820837.4A GB9820837D0 (en) 1998-09-24 1998-09-24 Pharmaceutical formulations
GBGB9903177.5A GB9903177D0 (en) 1999-02-13 1999-02-13 Pharmaceutical formulations

Publications (3)

Publication Number Publication Date
HU9902076D0 HU9902076D0 (en) 1999-08-30
HUP9902076A2 true HUP9902076A2 (hu) 2000-05-28
HUP9902076A3 HUP9902076A3 (en) 2002-03-28

Family

ID=27269368

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9902076A HUP9902076A3 (en) 1998-06-22 1999-06-21 Intranasal formulations for treating sexual disorders

Country Status (40)

Country Link
US (2) US20020040139A1 (hu)
EP (1) EP0967214B1 (hu)
JP (1) JP3263379B2 (hu)
KR (1) KR100345824B1 (hu)
AP (1) AP1178A (hu)
AR (1) AR016993A1 (hu)
AT (1) ATE269866T1 (hu)
AU (1) AU746865B2 (hu)
BG (1) BG64372B1 (hu)
BR (1) BR9903273A (hu)
CA (1) CA2275554C (hu)
CZ (1) CZ294856B6 (hu)
DE (1) DE69918222T2 (hu)
DK (1) DK0967214T3 (hu)
DZ (1) DZ2826A1 (hu)
EA (1) EA001903B1 (hu)
ES (1) ES2221733T3 (hu)
GT (1) GT199900095A (hu)
HN (1) HN1999000096A (hu)
HR (1) HRP990195B1 (hu)
HU (1) HUP9902076A3 (hu)
ID (1) ID23554A (hu)
IL (1) IL130539A0 (hu)
IS (1) IS5085A (hu)
MA (1) MA25089A1 (hu)
MY (1) MY117967A (hu)
NO (1) NO317365B1 (hu)
NZ (1) NZ336382A (hu)
OA (1) OA11069A (hu)
PA (1) PA8476301A1 (hu)
PE (1) PE20000702A1 (hu)
PT (1) PT967214E (hu)
SG (1) SG77246A1 (hu)
SI (1) SI0967214T1 (hu)
SK (1) SK284574B6 (hu)
TN (1) TNSN99129A1 (hu)
TR (1) TR199901444A2 (hu)
TW (1) TWI223598B (hu)
UA (1) UA59385C2 (hu)
YU (1) YU29699A (hu)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200591B1 (en) 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
GB9828340D0 (en) * 1998-12-22 1999-02-17 Novartis Ag Organic compounds
CA2391968A1 (en) * 1999-11-18 2001-05-25 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
KR20010016165A (ko) * 2000-11-16 2001-03-05 정순학 성기능 장애 치료를 위한 피부에 적용하는 제제
DE10118305A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Zusammensetzungen zur nasalen Applikation
DE10118306A1 (de) 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
AU2002310086B2 (en) * 2001-05-24 2008-09-04 Alexza Pharmaceuticals, Inc. Delivery of erectile dysfunction drugs through an inhalation route
DE10248601B4 (de) * 2002-10-17 2006-05-24 Goldstein, Naum, Dr.habil.nat. Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US7138107B2 (en) * 2003-02-18 2006-11-21 Compellis Pharmaceuticals Inhibition of olfactory neurosensory function to treat eating disorders and obesity
US7638138B2 (en) * 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
KR100974482B1 (ko) 2003-03-27 2010-08-10 가부시키가이샤 바이오악티스 비강용 분말 약제 투약 장치
AR043880A1 (es) * 2003-04-22 2005-08-17 Solvay Pharm Gmbh Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas
ATE510174T1 (de) 2003-05-21 2011-06-15 Alexza Pharmaceuticals Inc Schlag gezündete unabhängige heizeinheit
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US8673360B2 (en) * 2004-08-10 2014-03-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions that enable rapid-acting and highly absorptive intranasal administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
DK1802277T3 (da) 2004-10-18 2010-05-17 Polymun Scient Immunbio Forsch Liposomal sammensætning indeholdende en aktiv bestanddel til relaksation af glat muskulatur og terapeutisk anvendelse af sammensætningen
WO2006094924A2 (en) * 2005-03-09 2006-09-14 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and pde 5-inhibitors
ME01609B (me) 2005-04-19 2014-09-20 Takeda Gmbh Roflumilast za liječenje pulmonarne hipertenzije
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
EP1843770B1 (en) * 2005-08-29 2008-06-18 Teva Pharmaceutical Industries Ltd Solid particulate tadalafil having a bimodal particle size distribution
GB0526283D0 (en) * 2005-12-23 2006-02-01 Givaudan Sa Compositions
GB0606234D0 (en) * 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US8337817B2 (en) * 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
EP2121088B1 (en) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
DE102008004893A1 (de) * 2008-01-17 2009-07-23 Add Technologies Ltd. Trägerpellets, Verfahren zu deren Herstellung und deren Verwendung
WO2009098697A1 (en) * 2008-02-08 2009-08-13 Dexxon Ltd. Modafinil and sildenafil dosage forms
WO2009121039A2 (en) * 2008-03-28 2009-10-01 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
CA2726259C (en) 2008-06-04 2014-07-29 Colgate-Palmolive Company Oral care implement with cavitation system
US20100104624A1 (en) * 2008-06-11 2010-04-29 Peter Langecker Combination therapy using phosphodiesterase inhibitors
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
JP2012526726A (ja) * 2009-05-15 2012-11-01 株式会社新日本科学 薬物動態が改善された鼻腔内用薬学的組成物
JP2011001317A (ja) * 2009-06-19 2011-01-06 Fumakilla Ltd 鼻用洗浄剤
GB2472327B (en) * 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
KR20130030261A (ko) 2010-05-10 2013-03-26 유로-셀티큐 에스.에이. 활성제-무함유 과립 및 그를 포함하는 정제의 제조
JP5840201B2 (ja) 2010-05-10 2016-01-06 ユーロ−セルティーク エス．エイ． 活性剤を負荷した顆粒と追加の活性剤の組合せ
EP3415139B8 (en) 2011-06-14 2022-05-18 Neurelis, Inc. Administration of benzodiazepine
CN102952138B (zh) * 2011-08-17 2016-07-06 上海特化医药科技有限公司 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
WO2014055801A1 (en) * 2012-10-05 2014-04-10 Henkin Robert I Phosphodiesterase inhibitors for treating taste and smell disorders
CA2795324C (en) * 2012-11-09 2015-07-14 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
RU2536425C2 (ru) * 2013-01-17 2014-12-20 Общество с ограниченной ответственностью "Фармамед" Фармацевтическая композиция, содержащая силденафил цитрат, и способ ее приготовления
US20160030435A1 (en) * 2013-03-15 2016-02-04 Robert I HENKIN Phosphodiesterase inhibitor treatment
CN112716955A (zh) 2013-11-13 2021-04-30 欧洲凯尔特公司 用于治疗疼痛和阿片样物质肠功能障碍综合征的氢吗啡酮和纳洛酮
WO2015126944A1 (en) 2014-02-18 2015-08-27 Henkin Robert I Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
NO2723977T3 (hu) 2014-03-19 2018-03-10
CA2994709A1 (en) * 2015-08-03 2017-02-09 Synergistic Therapeutics, Llc Sexual dysfunction therapeutic gel
EP3532068A4 (en) * 2016-10-31 2020-04-29 Suda Ltd ADMINISTRATION OF ACTIVE INGREDIENTS BY MUCOSA
WO2018158234A1 (en) 2017-03-02 2018-09-07 Dutch Renewable Energy B.V. Intranasal administration of physiologically active substances
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
US11464778B2 (en) 2017-12-26 2022-10-11 Liqmeds Worldwide Limited Liquid oral formulations for sildenafil
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
AU2019254841A1 (en) * 2018-04-16 2020-12-03 Barista Mist Pty Ltd Caffeine compositions and methods of use
SE542968C2 (en) * 2018-10-26 2020-09-22 Lindahl Anders Treatment of osteoarthritis
US20220111162A1 (en) * 2020-07-29 2022-04-14 Lido Ventures Llc Apparatus, system, and method for facilitating intranasal treatment of a patient

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
YU49315B (sh) * 1995-11-20 2005-06-10 Elli Lilly And Company Inhibitor protein kinaze c, njegove farmaceutske formulacije i postupak za dobijanje
WO1998053819A1 (fr) * 1997-05-29 1998-12-03 Mochida Pharmaceutical Co., Ltd. Agent therapeutique destine a traiter l'anerection
AU751182B2 (en) * 1997-12-02 2002-08-08 Archimedes Development Limited Compositions for nasal administration
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase

Also Published As

Publication number Publication date
EA001903B1 (ru) 2001-10-22
EP0967214A1 (en) 1999-12-29
GT199900095A (es) 2000-12-13
US20030158206A1 (en) 2003-08-21
CZ9902257A3 (cs) 2000-11-15
NO993051D0 (no) 1999-06-21
HRP990195A2 (en) 2000-02-29
AU746865B2 (en) 2002-05-02
YU29699A (sh) 2003-02-28
SI0967214T1 (en) 2004-10-31
JP3263379B2 (ja) 2002-03-04
JP2000034232A (ja) 2000-02-02
CA2275554A1 (en) 1999-12-22
TWI223598B (en) 2004-11-11
HUP9902076A3 (en) 2002-03-28
AP9901585A0 (en) 1999-06-30
PE20000702A1 (es) 2000-08-16
HU9902076D0 (en) 1999-08-30
BR9903273A (pt) 2000-05-09
HRP990195B1 (en) 2003-04-30
BG103510A (en) 2000-01-31
DE69918222D1 (de) 2004-07-29
NZ336382A (en) 1999-11-29
AR016993A1 (es) 2001-08-01
PA8476301A1 (es) 2000-09-29
AU3579499A (en) 2000-01-06
NO317365B1 (no) 2004-10-18
CZ294856B6 (cs) 2005-03-16
KR100345824B1 (ko) 2002-07-24
IL130539A0 (en) 2000-06-01
HN1999000096A (es) 2000-12-03
TR199901444A2 (xx) 2000-01-21
EA199900487A3 (ru) 2000-04-24
PT967214E (pt) 2004-08-31
CA2275554C (en) 2003-06-03
NO993051L (no) 1999-12-23
EP0967214B1 (en) 2004-06-23
MA25089A1 (fr) 2000-12-31
DE69918222T2 (de) 2005-07-28
ES2221733T3 (es) 2005-01-01
SK81999A3 (en) 2001-01-18
TNSN99129A1 (fr) 2005-11-10
KR20000006310A (ko) 2000-01-25
SK284574B6 (sk) 2005-06-02
BG64372B1 (bg) 2004-12-30
ID23554A (id) 2000-05-04
MY117967A (en) 2004-08-30
DZ2826A1 (fr) 2003-12-01
IS5085A (is) 1999-12-23
SG77246A1 (en) 2000-12-19
EA199900487A2 (ru) 1999-12-29
AP1178A (en) 2003-06-30
US20020040139A1 (en) 2002-04-04
DK0967214T3 (da) 2004-09-27
OA11069A (en) 2002-03-13
ATE269866T1 (de) 2004-07-15
UA59385C2 (uk) 2003-09-15

Similar Documents

Publication Publication Date Title
HUP9902076A2 (hu) Szexuális rendellenességek kezelésére alkalmas intranazális készítmény
NO993520L (no) Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon
CY1105931T1 (el) Χρηση ενος αγωνιστη/ανταγωνιστη οιστρογονου για την αντιμετωπιση γυναικειας σεξουαλικης δυσλειτουργιας
ES2156028T3 (es) Composiciones que contienen tetrahidrolipstatina
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
IL151503A0 (en) Therapeutic combinations of antihypertensive and antiagiogenic agents
IL153297A0 (en) Compounds and compositions for delivering active agents
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
WO2002011711A3 (en) Formulations of mometasone and a bronchodilator for pulmonary administration
HK1051497A1 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
BR0210261A (pt) Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
TW200509998A (en) Controlled release of highly soluble agents
WO2002011694A3 (en) COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN ORAL CAVITY IN THE TREATMENT OF MYCOSIS
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
DE60119976D1 (en) Thixotropes nasenspray
SE0001916D0 (sv) Novel formulation
WO2001019357A3 (de) Kombinationspräparat zur behandlung von sexueller dysfunktion
SE0103210D0 (sv) New formulations and use thereof
ECSP982396A (es) Composiciones que contienen tetrahidrolipstatina